| Ramos, Carlos |
| Terminated | 3 | 205 | Europe, RoW | Plitidepsin, Dexamethasone, Remdesivir, Favipiravir | PharmaMar | COVID-19 Infection | 03/23 | 03/23 | | |
| Active, not recruiting | 3 | 9541 | Europe, Canada, Japan, US, RoW | Obicetrapib, Placebo | NewAmsterdam Pharma, Monash University | Atherosclerotic Cardiovascular Disease | 11/26 | 11/26 | | |
NCT05556824: Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD |
|
|
| Recruiting | 2 | 156 | US | MHS-1031, Panosyl-isomaltooligosaccharide, Placebo | Microbiome Health Sciences, VBHRC Virginia Catalyst | Gastroesophageal Reflux | 07/25 | 07/25 | | |
ACTION, NCT05352828: Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy |
|
|
| Active, not recruiting | 1b | 15 | US | Nivolumab, Opdivo, Autologous CD30.CAR-T, CD30-directed CAR-T cells, Fludarabine, Fludara, Bendamustine, Bendeka, Treanda | Tessa Therapeutics, Bristol-Myers Squibb | Classical Hodgkin Lymphoma, Hodgkin Disease Refractory, Hodgkin Disease Recurrent | 12/25 | 12/37 | | |
| Active, not recruiting | 1 | 3 | US | autologous or syngeneic PBTLs and EBV-CTLs | Baylor College of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital Research Institute | Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | 05/12 | 04/27 | | |
CRETI-NH, NCT00586391: CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL |
|
|
| Active, not recruiting | 1 | 14 | US | CD19CAR-28-zeta T cells, Ipilimumab, Yervoy | Baylor College of Medicine, The Methodist Hospital Research Institute, Center for Cell and Gene Therapy, Baylor College of Medicine | B Cell Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia | 07/14 | 07/29 | | |
ANCHOR, NCT00840853: Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT |
|
|
| Active, not recruiting | 1 | 68 | US | CD19CAR/virus specific T cells, Benadryl and Tylenol, Diphenhydramine and acetaminophen | Baylor College of Medicine, The Methodist Hospital Research Institute, Center for Cell and Gene Therapy, Baylor College of Medicine | Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Non Hodgkin's Lymphoma | 04/16 | 04/31 | | |
| Active, not recruiting | 1 | 7 | US | CD19.CAR-CD28Z T Cells - dose escalation 2, CD19.CAR-CD28Z T Cells - dose escalation 1 | Baylor College of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital Research Institute | Non-Hodgkin's Lymphoma, B-Cell ALL, B-Cell CLL | 10/19 | 12/30 | | |
| Active, not recruiting | 1 | 32 | US | HPV Specific T Cells, HPVSTs, Cytoxan, cyclophosphamide, Fludarabine, Fludara, Nivolumab, Opdivo | Baylor College of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital Research Institute | Human Papillomavirus-Related Carcinoma, Human Papillomavirus Positive Oropharyngeal Carcinoma, Human Papillomavirus Positive Cervical Carcinoma, Human Papillomavirus Positive Anal Carcinoma, Human Papillomavirus Positive Vulvar Carcinoma, Human Papillomavirus Positive Penile Carcinoma | 10/25 | 10/33 | | |
| Recruiting | 1 | 36 | US | KUR-502, CD19.CAR-aNKT cells | Athenex, Inc. | NHL, Relapsed, Adult, B-cell Lymphoma, B-cell Leukemia, DLBCL - Diffuse Large B Cell Lymphoma, ALL, Adult B Cell, ALL, Childhood, CLL/SLL | 12/23 | 12/24 | | |
ANCHOR, NCT03774654: CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies |
|
|
| Recruiting | 1 | 48 | US | CD19.CAR-aNKT cells | Baylor College of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital Research Institute | Refractory B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Small Lymphocytic Lymphoma, Relapsed Adult ALL, Relapsed CLL, Relapsed Non Hodgkin Lymphoma | 01/26 | 03/35 | | |
SAGAN, NCT01853631: Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL |
|
|
| Recruiting | 1 | 64 | US | Dose Escalation Phase:CD19.CAR/28 and CD19.CAR/28137 T cells, Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells | Baylor College of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital Research Institute | Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia | 12/25 | 02/36 | | |
CHARKALL, NCT00881920: Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, |
|
|
| Recruiting | 1 | 54 | US | Kappa CD28 T cells | Baylor College of Medicine, The Methodist Hospital Research Institute, Center for Cell and Gene Therapy, Baylor College of Medicine | Lymphoma, Myeloma, Leukemia | 01/25 | 07/35 | | |
NCT04288726: Allogeneic CD30.CAR-EBVSTs in Patients with Relapsed or Refractory CD30-Positive Lymphomas |
|
|
| Recruiting | 1 | 18 | US | CD30.CAR-EBVST cells, Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes | Baylor College of Medicine, The Methodist Hospital Research Institute | Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, Classical Hodgkin Lymphoma | 06/25 | 06/37 | | |
NCT02917083: CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30) |
|
|
| Recruiting | 1 | 60 | US | CAR T Cells, CD30.CAR T Cells | Baylor College of Medicine, The Methodist Hospital Research Institute | Hodgkin's Lymphoma, Non-Hodgkin Lymphoma | 04/26 | 02/40 | | |
VASOTENS, NCT02577835: International Registry for Ambulatory Blood Pressure and Arterial Stiffness Telemonitoring |
|
|
| Completed | N/A | 2000 | Europe, RoW | Ambulatory blood pressure monitoring | Italian Institute of Telemedicine, BPLab | Hypertension | 12/18 | 04/22 | | |
NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients |
|
|
| Available | N/A | | Canada, US, RoW | CTL019, tisagenlecleucel, Kymriah | Novartis Pharmaceuticals | Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL) | | | | |
